Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - paul+erhardt
8
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Novel Therapeutics for Osteoporosis, Osteoarthritis and Other Musculoskeletal Diseases
Project ID: D2013-47 Novelty: Three categories of drug-like molecules that have been identified to promote bone and cartilage formation from stem cells. Value Proposition: Osteoporosis and Osteoarthritis are complex musculoskeletal diseases that are prevalent in the aging population. Worldwide,...
Published: 4/20/2026
|
Updated: 4/20/2026
|
Inventor(s):
Bruce Heck
,
Dong Hyun "Danny" Kim
,
Paul Erhardt
,
Brian Kress
Keywords(s):
Agonists
,
Antagonists
,
Musculoskeletal
,
Osteoarthritis
,
Osteoporosis
Category(s):
Long Bone/Joint Repair
Confederated C Prime Agents vs Cancers (PDAC) & Metabolic Disorders
Project ID: D2020-28 Based upon the success of a mixture of simvastatin (SIM) + metformin (Met) + digoxin (Dig), dubbed “C3”, for treating pancreatic ductal adenocarcinoma (PDAC) via a pleiotropic mechanism where attenuation of the BIRC5 pathway is a major component, we have pursued novel, single-molecular constructs that combine features...
Published: 4/6/2026
|
Updated: 6/4/2025
|
Inventor(s):
Paul Erhardt
,
Shi-He Liu
,
F. Charles Brunicardi
,
Divya Andy
Keywords(s):
Category(s):
Oncology
Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same
Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone loss. There are currently no drugs developed to raise bone mass to normal...
Published: 4/15/2026
|
Updated: 3/27/2025
|
Inventor(s):
Bruce Heck
,
Paul Erhardt
,
Brian Kress
,
DongHyun Kim
Keywords(s):
Category(s):
Long Bone/Joint Repair
,
Oncology
Advancement in Platinum Based Cancer Therapeutics
One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells. Although increased DNA repair has been shown to be a major mechanism of cancer drug resistance, not much was done until recently to address this challenge. The researchers at The University of Toledo have discovered small drug like molecules...
Published: 4/16/2026
|
Updated: 1/2/2025
|
Inventor(s):
Stephan Patrick
,
Paul Erhardt
Keywords(s):
Cisplatin
,
Clinical Trials
,
DNA Repair
,
Ovarian Cancer
,
Platinum
Category(s):
Oncology
Compounds for non-lethal micropinocytosis and exosome production
Project ID: D2017-25 Background Exosomes are vesicles in the range of 30 to 120nm, which are released from mammalian cells when multi-vesicular endosomes fuse with the plasma membrane. In recent times, exosomes have been implicated in cancer. Mounting evidence suggests that exosomes play an important role in mediating intercellular communication...
Published: 10/2/2025
|
Updated: 2/7/2022
|
Inventor(s):
William Maltese
,
Paul Erhardt
,
Zehui (Lesley) Li
,
Christopher Trabbic
Keywords(s):
Cancer
,
Exosome
,
Vacuole
,
Vesicle
Category(s):
Neuroscience
,
Oncology
,
Diagnostics
Compounds for disrupting microtubule networks and mitosis in brain cancer
Project ID: D2014-42 Background Primary brain tumors and secondary intracranial tumors from metastatic spread of other cancers (e.g., melanoma, lung carcinoma) have been inaccessible to therapy with microtubule-targeted agents (vincristine, vinblastine, paclitaxel) because the latter do not readily cross the blood-brain barrier. Invention...
Published: 2/12/2026
|
Updated: 2/7/2022
|
Inventor(s):
William Maltese
,
Paul Erhardt
,
Christopher Trabbic
,
Jean Overmeyer
Keywords(s):
Category(s):
Neuroscience
,
Oncology
Cancer Therapy via Simultaneous Non-apoptotic Cell Death Mechanisms
Project ID: D2018-15 Most current cancer therapies rely on agents that trigger apoptotic (programmed) cell-death pathways. During treatment, tumors can acquire mutations that diminish apoptotic responses and become chemoresistant, often accompanied by increased drug efflux and enhanced DNA repair. This resistance contributes to therapeutic failure, particularly...
Published: 4/15/2026
|
Updated: 7/30/2020
|
Inventor(s):
Amit Tiwari
,
Chandrabose Karthikeyan
,
Haneen Amawi
,
Paul Erhardt
,
Piyush Trivedi
Keywords(s):
Autophagy
,
Cancer
,
Drug-resistance
,
Methuosis
,
Non-apoptotic cell death
Category(s):
Oncology
Advancement in Platinum Based Cancer Therapeutics
Project ID: D2014-33Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells....
Published: 6/18/2024
|
Updated: 8/19/2014
|
Inventor(s):
Paul Erhardt
,
Stephan Patrick
,
Christopher Trabbic
Keywords(s):
Cisplatin
,
Clinical Trials
,
DNA Repair
,
Ovarian Cancer
,
Platinum
Category(s):
Oncology
,
Tools